FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2253479946> ?p ?o ?g. }

• W2253479946 endingPage "1546" @default.
• W2253479946 startingPage "1538" @default.
• W2253479946 abstract "PURPOSE To evaluate the effectiveness of adding interferon (IFN) alfa-2b to chemotherapy in the induction treatment of low-grade non-Hodgkin's lymphoma (NHL), and to assess the role of maintenance IFN. PATIENTS AND METHODS A multicenter, two-phase controlled trial with double randomization was conducted in 155 patients with low-grade NHL. In the first randomization, 78 patients received cyclophosphamide, vincristine, and prednisone (CVP) and IFN, 3 MU/m2 three times a week for 3 months, and 77 patients received CVP alone. Responding patients were randomized to receive IFN for 1 year versus observation. RESULTS Of 144 assessable patients, 73 received CVP + IFN and 71 received CVP. Responses were similar: CVP + IFN 79% versus CVP 76% (P = .62). The number of patients who did not complete the treatment was higher in the CVP + IFN group than in the CVP group (18% v 4%; P = .009), although the received dose-intensity of chemotherapy was comparable. Duration of response and progression-free survival (PFS) were significantly higher in the CVP + IFN group than in the CVP group (P = .0004). However, we observed no differences in overall survival (OS) (P = .30), with a median follow-up for the surviving patients of 3 years. Grade 3/4 granulocytopenia was the most frequent toxicity and was similar in both groups (33% v32%). Eighty-three (74%) of the 112 responding patients were randomized to maintenance IFN or observation. The duration of response was similar between 42 patients that received IFN compared with 41 control patients (P = .83), independently of treatment previously administered. CONCLUSION Adding IFN alfa-2b to induction CVP in low-grade NHL did not induce a higher response rate, but it significantly increased the duration of the responses. We found significant differences in PFS that favored the patients who received CVP + IFN, but not in OS. To date, no additional benefit has been seen from the administration of IFN for maintenance." @default.
• W2253479946 created "2016-06-24" @default.
• W2253479946 creator A5009262129 @default.
• W2253479946 creator A5022086773 @default.
• W2253479946 creator A5037716403 @default.
• W2253479946 creator A5041241624 @default.
• W2253479946 creator A5045855418 @default.
• W2253479946 creator A5047212285 @default.
• W2253479946 creator A5047280933 @default.
• W2253479946 creator A5052403587 @default.
• W2253479946 creator A5061555567 @default.
• W2253479946 creator A5066100862 @default.
• W2253479946 creator A5067403397 @default.
• W2253479946 creator A5073475352 @default.
• W2253479946 creator A5075599473 @default.
• W2253479946 creator A5076059050 @default.
• W2253479946 creator A5085064773 @default.
• W2253479946 creator A5090464803 @default.
• W2253479946 date "1998-04-01" @default.
• W2253479946 modified "2023-10-16" @default.
• W2253479946 title "Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization." @default.
• W2253479946 cites W1595896331 @default.
• W2253479946 cites W1874821077 @default.
• W2253479946 cites W1885678484 @default.
• W2253479946 cites W1985643183 @default.
• W2253479946 cites W1992964537 @default.
• W2253479946 cites W1996285570 @default.
• W2253479946 cites W1996549520 @default.
• W2253479946 cites W2006075926 @default.
• W2253479946 cites W2017358407 @default.
• W2253479946 cites W2034902182 @default.
• W2253479946 cites W2060117309 @default.
• W2253479946 cites W2077485687 @default.
• W2253479946 cites W2077937762 @default.
• W2253479946 cites W2088920936 @default.
• W2253479946 cites W2093312029 @default.
• W2253479946 cites W2097411619 @default.
• W2253479946 cites W2144360148 @default.
• W2253479946 cites W2167805334 @default.
• W2253479946 cites W2170134215 @default.
• W2253479946 cites W2171796002 @default.
• W2253479946 cites W2265869613 @default.
• W2253479946 cites W2292226371 @default.
• W2253479946 cites W2328311363 @default.
• W2253479946 cites W2339387502 @default.
• W2253479946 cites W2344245690 @default.
• W2253479946 doi "https://doi.org/10.1200/jco.1998.16.4.1538" @default.
• W2253479946 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9580385" @default.
• W2253479946 hasPublicationYear "1998" @default.
• W2253479946 type Work @default.
• W2253479946 sameAs 2253479946 @default.
• W2253479946 citedByCount "57" @default.
• W2253479946 countsByYear W22534799462012 @default.
• W2253479946 countsByYear W22534799462013 @default.
• W2253479946 countsByYear W22534799462018 @default.
• W2253479946 countsByYear W22534799462019 @default.
• W2253479946 countsByYear W22534799462020 @default.
• W2253479946 crossrefType "journal-article" @default.
• W2253479946 hasAuthorship W2253479946A5009262129 @default.
• W2253479946 hasAuthorship W2253479946A5022086773 @default.
• W2253479946 hasAuthorship W2253479946A5037716403 @default.
• W2253479946 hasAuthorship W2253479946A5041241624 @default.
• W2253479946 hasAuthorship W2253479946A5045855418 @default.
• W2253479946 hasAuthorship W2253479946A5047212285 @default.
• W2253479946 hasAuthorship W2253479946A5047280933 @default.
• W2253479946 hasAuthorship W2253479946A5052403587 @default.
• W2253479946 hasAuthorship W2253479946A5061555567 @default.
• W2253479946 hasAuthorship W2253479946A5066100862 @default.
• W2253479946 hasAuthorship W2253479946A5067403397 @default.
• W2253479946 hasAuthorship W2253479946A5073475352 @default.
• W2253479946 hasAuthorship W2253479946A5075599473 @default.
• W2253479946 hasAuthorship W2253479946A5076059050 @default.
• W2253479946 hasAuthorship W2253479946A5085064773 @default.
• W2253479946 hasAuthorship W2253479946A5090464803 @default.
• W2253479946 hasConcept C121608353 @default.
• W2253479946 hasConcept C126322002 @default.
• W2253479946 hasConcept C141071460 @default.
• W2253479946 hasConcept C168563851 @default.
• W2253479946 hasConcept C204243189 @default.
• W2253479946 hasConcept C2775965419 @default.
• W2253479946 hasConcept C2776694085 @default.
• W2253479946 hasConcept C2776755627 @default.
• W2253479946 hasConcept C2777701055 @default.
• W2253479946 hasConcept C2778720950 @default.
• W2253479946 hasConcept C2779429289 @default.
• W2253479946 hasConcept C2781228144 @default.
• W2253479946 hasConcept C2992435398 @default.
• W2253479946 hasConcept C71924100 @default.
• W2253479946 hasConcept C90924648 @default.
• W2253479946 hasConceptScore W2253479946C121608353 @default.
• W2253479946 hasConceptScore W2253479946C126322002 @default.
• W2253479946 hasConceptScore W2253479946C141071460 @default.
• W2253479946 hasConceptScore W2253479946C168563851 @default.
• W2253479946 hasConceptScore W2253479946C204243189 @default.
• W2253479946 hasConceptScore W2253479946C2775965419 @default.
• W2253479946 hasConceptScore W2253479946C2776694085 @default.
• W2253479946 hasConceptScore W2253479946C2776755627 @default.
• W2253479946 hasConceptScore W2253479946C2777701055 @default.

• next